Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: A randomized, controlled trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 3, 2013, Pages 279-283

  Gupta, Samir K ^a   Mi, Deming ^a   Moe, Sharon M ^a   Dubé, Michael P ^a,b   Liu, Ziyue ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

efavirenz; endothelial function; monocyte activation; raltegravir; renal function; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CD14 ANTIGEN; EFAVIRENZ; EMTRICITABINE; PARATHYROID HORMONE; RALTEGRAVIR; TENOFOVIR; 2 PYRROLIDONE DERIVATIVE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; CHOLESTEROL; DEOXYCYTIDINE; DRUG COMBINATION; EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; OXAZINE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE MINERAL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; ENDOTHELIUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; KIDNEY FUNCTION; MINERAL METABOLISM; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BLOOD; BONE; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HIV INFECTIONS; KIDNEY FAILURE; MALE; METABOLISM; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIUM; VIRUS LOAD;

ADENINE; ADULT; ALKALINE PHOSPHATASE; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; BONE AND BONES; C-REACTIVE PROTEIN; CHOLESTEROL; DEOXYCYTIDINE; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; INDIANA; INFLAMMATION; MALE; ORGANOPHOSPHONATES; OXAZINES; PYRROLIDINONES; RENAL INSUFFICIENCY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84886387920     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a97c39     Document Type: Article

References (32)

1. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;6:397-406.
2. Gupta SK, Shen C, Moe SM, et al. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One. 2012;9:e45716.
3. Kristoffersen US, Wiinberg N, Petersen CL, et al. Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation. Nucl Med Commun. 2010;10:874-880.
4. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;17:1723-1735.
5. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;7:445-456.
6. BarenbrockM, Hausberg M, KoschM, et al. Effect of hyperparathyroidism on arterial distensibility in renal transplant recipients. Kidney Int. 1998;1: 210-215.
7. Baykan M, Erem C, Erdogan T, et al. Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. Int J Cardiovasc Imaging. 2007;3:323-328.
8. Ekmekci A, Abaci N, Colak Ozbey N, et al. Endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism. J Endocrinol Invest. 2009;7:611-616.
9. Jolma P, Koobi P, Kalliovalkama J, et al. Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure. Nephrol Dial Transplant. 2003;12:2560-2569.
10. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;2:257-265.
11. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976;1:31-41.
12. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;9:604-612.
13. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;1:20-29.
14. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;7:412-419.
15. Masia M, Martinez E, Padilla S, et al. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. J Antimicrob Chemother. 2013; 2:409-413.
16. Hatano H, Scherzer R, Wu Y, et al. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr. 2012;3:317-325.
17. Brown TT, McComsey GA Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;3:425-429.
18. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;12: 1923-1928.
19. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;11:1697-1707.
20. Lake JE, McComsey GA, Hulgan TM, et al. A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012;9:532-540.
21. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;9692:796-806.
22. Gallant JE, Moore RD Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;15:1971-1975.
23. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;1:102-108.
24. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and paraaminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;4:990-996.
25. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;6:780-790.
26. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;8:1227-1236.
27. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA. 2012;4:379-386.
28. Asmuth DM, Ma Z-M, Mann S, et al. Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. AIDS. 2012;13:1625-1634.
29. Patterson KB, Prince HA, Stevens T, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS. 2013;27:1413-1419.
30. Nielsen MJ, Moller HJ, Moestrup SK Hemoglobin and heme scavenger receptors. Antioxid Redox Signal. 2010;2:261-273.
31. Kathiresan S, Gona P, Larson MG, et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation. 2006;7:938-945.
32. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate- risk individuals. JAMA. 2012;8:788-795.